Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model.
Acupuncture is frequently used as an alternative therapy for Parkinson's disease (PD), and it attenuates dopaminergic (DA) neurodegeneration in the substantia nigra (SN) in PD animal models. Using proteomic analysis, we investigated whether acupuncture alters protein expression in the SN to favor attenuation of neuronal degeneration. In C57BL/6 mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30 mg/kg/day), intraperitoneal (i.p.) for 5 days, 2 or 100 Hz electroacupuncture (EA) was applied at the effective and specific acupoint, GB34, once a day for 12 consecutive days from the first MPTP treatment. Both treatments in MPTP mice led to restoration of behavioral impairment and rescued tyrosine hydroxylase (TH)-positive DA neurodegeneration. Using peptide fingerprinting MS, we identified changes in 22 proteins in the SN following MPTP treatment, and nine of these proteins were normalized by EA. They were involved in cell death regulation, inflammation, or restoration from damage. The levels of cyclophilin A (CypA), which is a neuroprotective agent, were unchanged by MPTP treatment but were increased in MPTP-EA mice. These results suggest that acupoint GB34-specific EA changes protein expression profiles in the SN in favor of DA neuronal survival in MPTP-treated mice, and that EA treatment may be an effective therapy for PD patients.
Jeon
Songhee
S
Medical Science Research Center, Dongguk University, Gyeonggi-Do, Republic of Korea.
Kim
Youn Jung
YJ
Kim
Seung-Tae
ST
Moon
Woongjoon
W
Chae
Younbyoung
Y
Kang
Minjeong
M
Chung
Mi-Young
MY
Lee
Hyangsook
H
Hong
Mi-Sook
MS
Chung
Joo-Ho
JH
Joh
Tong H
TH
Lee
Hyejung
H
Park
Hi-Joon
HJ
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D015669:Acupuncture Points; D000704:Analysis of Variance; D000818:Animals; D019208:Brain-Derived Neurotrophic Factor; D021984:Cyclophilin A / Q000378:metabolism; D015259:Dopamine Agents / Q000494:pharmacology; D015671:Electroacupuncture; D015180:Electrophoresis, Gel, Two-Dimensional; D005786:Gene Expression Regulation; D051379:Mice; D023421:Models, Animal; D009474:Neurons; D010300:Parkinson Disease / Q000628:therapy*; D010449:Peptide Mapping; D020543:Proteome / Q000235:genetics / Q000378:metabolism*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013378:Substantia Nigra / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D019208:Brain-Derived Neurotrophic Factor; D015259:Dopamine Agents; D020543:Proteome; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; D021984:Cyclophilin A